UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2174-8
Program Prior Authorization/Medical Necessity
Medication Wakix® (pitolisant)
P&T Approval Date 10/2019, 12/2019, 4/2020, 3/2021, 6/2021, 6/2022, 10/2023, 9/2024
Effective Date 12/1/2024
1. Background:
Wakix is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of
excessive daytime sleepiness (EDS) or cataplexy in adult and pediatric patients 6 years of age and
older with narcolepsy.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
© 2024 UnitedHealthcare Services, Inc.
1
A. Narcolepsy without Cataplexy (i.e., Narcolepsy Type 2)
1. Initial Authorization
a. Wakix will be approved based on all of the following criteria:
(1) Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of
narcolepsy with both of the following:
(a) The patient has daily periods of irrepressible need to sleep or daytime lapses into
sleep occurring for at least three months.
(b) A mean sleep latency of ≤ 8 minutes and two or more sleep onset REM periods
(SOREMPs) are found on a MSLT performed according to standard techniques
following a normal overnight polysomnogram. A SOREMP (within 15 minutes of
sleep onset) on the preceding nocturnal polysomnogram may replace one of the
SOREMPs on the MSLT.
-AND-
(2) Physician attestation to the following:
(a) Other causes of sleepiness have been ruled out or treated (including but not limited to
obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of
substances or medications or their withdrawal, sleep phase disorder, or other sleep
disorders).
-AND-
(3) One of the following:
(a) History of failure, contraindication, or intolerance to all of the following:
(i) armodafinil (Nuvigil) or modafinil (Provigil)
(ii) an amphetamine (e.g., amphetamine, dextroamphetamine) or methylphenidate
based stimulant
(iii) Sunosi
-OR-
(b) History of or potential for a substance abuse disorder
-AND-
(4) Prescribed by or in consultation with one of the following:
(a) Neurologist
(b) Psychiatrist
(c) Pulmonologist
© 2024 UnitedHealthcare Services, Inc.
2
(d) Sleep Medicine Specialist
Authorization will be issued for 12 months.
2. Reauthorization
a. Wakix will be approved for continuation of therapy based on the following criterion:
(1) Reduction in symptoms of excessive daytime sleepiness associated with Wakix therapy
Authorization will be issued for 12 months.
B. Narcolepsy with Cataplexy (i.e., Narcolepsy Type 1)
1. Initial Authorization
a. Wakix will be approved based on all of the following criteria:
(1) Submission of medical records (e.g. chart notes, lab values) documenting a diagnosis of
narcolepsy with cataplexy (i.e., Narcolepsy Type 1) with both of the following:
(a) The patient has daily periods of irrepressible need to sleep or daytime lapses into
sleep occurring for at least three months.
(b) A mean sleep latency of ≤ 8 minutes and two or more sleep onset REM periods
(SOREMPs) are found on a MSLT performed according to standard techniques
following a normal overnight polysomnogram. A SOREMP (within 15 minutes of
sleep onset) on the preceding nocturnal polysomnogram may replace one of the
SOREMPs on the MSLT.
-AND-
(2) Physician attestation to both of the following:
(a) Patient has experienced cataplexy defined as more than one episode of sudden loss of
muscle tone with retained consciousness
-AND-
(b) Other causes of sleepiness have been ruled out or treated (including but not limited to
obstructive sleep apnea, insufficient sleep syndrome, shift work, the effects of
substances or medications or their withdrawal, sleep phase disorder, or other sleep
disorders).
-AND-
(3) Prescribed by or in consultation with one of the following:
© 2024 UnitedHealthcare Services, Inc.
3
(a) Neurologist
(b) Psychiatrist
(c) Pulmonologist
(d) Sleep Medicine Specialist
Authorization will be issued for 12 months.
2. Reauthorization
a. Wakix will be approved for continuation of therapy based on one of the following criteria:
(1) Reduction in frequency of cataplexy attacks associated with therapy
–OR–
(2) Reduction in symptoms of excessive daytime sleepiness associated with therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan
coverage may also impact coverage criteria. Other policies and utilization management programs may
apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Wakix [package insert]. Plymouth Meeting, PA: Harmony Biosciences, LLC; June 2024.
2. American Academy of Sleep Medicine. International Classification of Sleep Disorders:
Diagnostic and Coding Manual. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
3. Sunosi [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; October 2021.
4. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: An
American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep
Medicine. 2021. Sept (17):1881-1893.
5. Wise MS1, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of
central origin. Sleep. 2007 Dec;30(12):1712-27.
Program Prior Authorization/Medical Necessity - Wakix® (pitolisant)
Change Control
11/2019 New program
12/2019 Added requirement for history of Sunosi.
4/2020 Added requirement for submission of documentation of sleep study
with specific sleep study requirements. Added requirement for
© 2024 UnitedHealthcare Services, Inc.
4
prescriber specialty. Changed initial authorization duration to 12
months.
3/2021 Added criteria for narcolepsy with cataplexy based on updated product
labeling.
6/2021 Updated Type 1 narcolepsy section to clarify that medical records
submitted show narcolepsy with cataplexy and provider attestation for
cataplexy symptoms. Added pulmonologist to the list of specialists.
6/2022 Annual review. Updated references.
10/2023 Annual review. Updated references.
9/2024 Annual review. Updated references.
© 2024 UnitedHealthcare Services, Inc.
5